Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of NKTR-214 plus nivolumab vs nivolumab in untreated unresectable or metastatic melanoma
2018-001423-40Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in melanoma comparing NKTR-214 plus nivolumab with Nivolumab monotherapy (2 arms). Primary endpoint: Overall response rate by BICR. Started Aug 2018; status: completed.
02
Drugs
bempegaldesleukinnivolumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2018-001423-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001423-40.